Você procurou por: progresuojancija (Lituano - Inglês)

kurie serga antrine progresuojancija isstine skleroze, jei liga aktyvi, kaip rodo atkryciai.
who suffer from secondary progressive multiple sclerosis with active disease shown by relapses.

· ligoniams, su antrine progresuojancija isstine skleroze, jei ji aktyvi, aktyvum rodo atkryciai.
· patients with secondary progressive multiple sclerosis with active disease, evidenced by

kai kuriais atvejais ligoniai, sergantys kartotine remituojancija is, pastebi, kad j simptomai sustiprja ir jiems issivysto kita is forma, vadinama antrine progresuojancija is.
in some cases people with relapsing-remitting ms find that their symptoms increase and they progress to another form of ms called secondary progressive ms.

nerekomenduojama gydyti ligoni, serganci kartotine remituojancija isstine skleroze, jei per pastaruosius 2 metus buvo maziau negu 2 atkryciai, ir antrine progresuojancija isstine skleroze, jei 2 metus liga nebuvo aktyvi.
treatment is not recommended in patients with relapsing-remitting multiple sclerosis who have experienced less than 2 relapses in the previous 2 years or in patients with secondary-progressive multiple sclerosis who have had no active disease in the previous 2 years.

kol kas nezinoma, kaip ilgai ligon reikia gydyti. yra iki 5 met trukms ankstesni kontroliuojamj klinikini tyrim duomenys pacientams, su kartotine remituojancija isstine skleroze, ir iki 3 met trukms pacientams, su antrine progresuojancija isstine skleroze.
at the present time, it is not known for how long the patient should be treated.there are follow-up data under controlled clinical conditions for patients with relapsing-remitting ms for up to 5 years and for patients with secondary progressive ms for up to 3 years.

kol kas nezinoma, kaip ilgai ligon reikia gydyti. yra iki 5 met trukms paskesni kontroliuojamj klinikini tyrim duomenys pacientams, su kartotine remituojancija isstine skleroze, ir iki 3 met trukms pacientams, su antrine progresuojancija isstine skleroze. kartotins remituojanciosios is gydymo veiksmingumas buvo nustatytas pirmus du metus.
at the present time, it is not known for how long the patient should be treated.there are follow-up data under controlled clinical conditions for patients with relapsing-remitting ms for up to 5 years and for patients with secondary progressive ms for up to 3 years.for relapsing-remitting ms, efficacy has been demonstrated for therapy for the first two years.